Natco Pharma 52 Week Week High ₹ 1639
Natco Pharma 52 Week Week Low ₹ 726
Why Natco Pharma Declined ?
The Company declined from the Highest of ₹ 1639 to ₹ 726 in previous , However the stock is declining from the Sep-2024 due to the global uncertanity but the stock dropped heavily in December post Q3Y25.
The decline was primarily due to a sharp drop in export formulation sales, which fell from ₹605 crore in Dec-23 to ₹286 crore in Dec-24—a 53% decrease. This was largely driven by a significant reduction in Revlimid sales, the company’s main revenue contributor, which had a substantial impact on overall financial performance.
Read More on Market Barrister
EaseMyTrip is the 2nd largest Online Travel Platform in India founded in 2008
Natco Pharma Q4FY2025 Strong Performance
Natco Pharma’s Q4 FY2025 financial results have shown strong performance. The stock has also recorded a notable improvement compared to Q3 FY2025.
Total sales for Q4 FY2025 stood at ₹1,221 crore, compared to ₹1,068 crore in the same quarter last year, marking a solid year-on-year growth. Notably, the company reported a remarkable 200+% increase in Profit After Tax (PAT), reaching ₹406 crore in Q4 FY2025, up from ₹132 crore in Q3 FY2025.
About Natco Pharma
Natco Pharma Limited is a vertically integrated and innovation-led pharmaceutical company engaged in the development, manufacturing, and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). With a strong focus on niche therapies and complex generics, Natco has established a presence in over 50 countries.
The company markets its FDF products across key regions including the United States, India, Europe, and other international markets, and operates in select geographies through its subsidiaries. Natco has built a strong reputation as a reliable, high-quality manufacturer of niche Active Pharmaceutical Ingredients (APIs), with a track record of producing over 50 APIs. While oncology remains our primary therapeutic focus, broadening our portfolio to include products in Central Nervous System (CNS) disorders, pain management, and cardiovascular care. Natco consistently creates first-to-market opportunities for its partners and customers.
Natco Pharma on Monthly Chart
The chart looks attractive on monthly basis, However after making a low of ₹ 757 the stock gain the break out in the upward direction with the strong volume , Stock has gained the momentum of 20% in last three months and performing good on NSE & BSE.
Natco Pharma Delivers Strong Annual Performance with Exceptional Quarterly Surge
Over the past year, Natco Pharma has consistently delivered strong performance and maintained healthy profitability. In the most recent quarter, the company recorded a remarkable increase in sales, accompanied by a sharp surge in Profit After Tax (PAT). This robust financial performance is further reinforced by a significant rise in trading volumes on the monthly charts, reflecting strong market confidence.
Disclaimer
The information provided on this website is for educational and informational purposes only and should not be considered as financial, investment, or trading advice. All content, including stock analyses, market data, and opinions, is based on publicly available information believed to be accurate at the time of publication.
Vedanta Demerger in five Verticals-Promoters stake 100% Pledge & Q3Y24 Result
Discover more from MARKET BARRISTER
Subscribe to get the latest posts sent to your email.
